GlassScriptPhysician profile
Kala Swamynathan
NPI 1427029768
$1,712.28
in general payments reported to CMS, 2019-2025
19 companies · $221 in 2025
The $221 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $19.22 · 2021: $164 · 2022: $312 · 2023: $274 · 2024: $531 · 2025: $221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998 · Entertainment: $26.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.03 |
| Entertainment | $26.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $252.65 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $237.00 | 2022-2025 | Miebo, Xiidra, Alrex |
| Sun Pharmaceutical Industries INC. | $230.90 | 2019-2025 | Cequa |
| Alcon Vision LLC | $169.29 | 2021-2024 | Rocklatan, Clareon |
| Oyster Point Pharma, INC. | $144.50 | 2022-2024 | Tyrvaya, Ryzumvi, Tyrvaya |
| Novartis Pharmaceuticals Corporation | $126.86 | 2019-2023 | |
| Abbvie INC. | $85.70 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $75.17 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $63.10 | 2022-2023 | Tecnis Iol, Veritas Vision System |
| Allergan, INC. | $57.41 | 2019-2021 | |
| Optos, INC. | $49.22 | 2019-2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Aerie Pharmaceuticals, INC. | $47.85 | 2019 | |
| Dompe US, INC. | $46.00 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $26.74 | 2023 | Acuvue |
| Thea Pharma INC. | $24.04 | 2025 | Iyuzeh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.79 | 2019 | |
| Harrow Eye, LLC | $22.37 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $17.49 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $13.20 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Swamynathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.